DK2212349T3 - Syntetiske analoger af nerveregenationspeptider - Google Patents
Syntetiske analoger af nerveregenationspeptiderInfo
- Publication number
- DK2212349T3 DK2212349T3 DK08840727.5T DK08840727T DK2212349T3 DK 2212349 T3 DK2212349 T3 DK 2212349T3 DK 08840727 T DK08840727 T DK 08840727T DK 2212349 T3 DK2212349 T3 DK 2212349T3
- Authority
- DK
- Denmark
- Prior art keywords
- nerve regeneration
- synthetic analogs
- regeneration peptides
- peptides
- analogs
- Prior art date
Links
- 210000005036 nerve Anatomy 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 230000008929 regeneration Effects 0.000 title 1
- 238000011069 regeneration method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2878—Muscular dystrophy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2878—Muscular dystrophy
- G01N2800/2892—Myotonic dystrophy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99929207P | 2007-10-17 | 2007-10-17 | |
| US99950307P | 2007-10-18 | 2007-10-18 | |
| PCT/US2008/011951 WO2009051844A1 (en) | 2007-10-17 | 2008-10-17 | Synthetic analogues of neural regeneration peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2212349T3 true DK2212349T3 (da) | 2013-11-04 |
Family
ID=40567715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08840727.5T DK2212349T3 (da) | 2007-10-17 | 2008-10-17 | Syntetiske analoger af nerveregenationspeptider |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US8309684B2 (da) |
| EP (1) | EP2212349B1 (da) |
| JP (1) | JP5425086B2 (da) |
| AU (1) | AU2008314565B2 (da) |
| CY (1) | CY1114619T1 (da) |
| DK (1) | DK2212349T3 (da) |
| ES (1) | ES2433568T3 (da) |
| HR (1) | HRP20131016T1 (da) |
| NZ (1) | NZ585363A (da) |
| PL (1) | PL2212349T3 (da) |
| PT (1) | PT2212349E (da) |
| WO (1) | WO2009051844A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2212349T3 (da) | 2007-10-17 | 2013-11-04 | Curonz Holdings Company Ltd | Syntetiske analoger af nerveregenationspeptider |
| WO2012102625A2 (en) * | 2011-01-28 | 2012-08-02 | Curonz Holdings Company Limited | Therapeutic composition |
| WO2012105854A2 (en) * | 2011-01-31 | 2012-08-09 | Curonz Holdings Company Limited | Compositions for administration to the eye |
| WO2014017927A1 (en) | 2012-07-27 | 2014-01-30 | Curonz Holdings Company Limited | Method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury |
| AU2014226650A1 (en) * | 2013-03-08 | 2015-10-01 | Curonz Holdings Company Limited | Neural regeneration peptides and uses therefor |
| WO2015084188A2 (en) | 2013-12-04 | 2015-06-11 | Curonz Holdings Company Limited | Method of treating or preventing epilepsy or seizures using one or more neural regeneration peptides |
| ES2865624T3 (es) * | 2013-12-20 | 2021-10-15 | Univ Manitoba | Métodos y composiciones para el tratamiento de neuropatías periféricas |
| WO2015194970A2 (en) * | 2014-06-20 | 2015-12-23 | Curonz Holdings Company Limited | Method of treating or preventing multiple sclerosis using one or more neural regeneration peptides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995032003A1 (en) | 1994-05-24 | 1995-11-30 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| AU2002335657A1 (en) * | 2001-08-24 | 2003-03-10 | Neuronz Biosciences, Inc. | Neural regeneration peptide and methods for their use in treatment of brain damage |
| US7563862B2 (en) * | 2001-08-24 | 2009-07-21 | Neuren Pharmaceuticals Limited | Neural regeneration peptides and methods for their use in treatment of brain damage |
| EP1553963A4 (en) * | 2002-09-24 | 2006-05-03 | Burnham Inst | NEW MEANS FOR MODULATING EPH RECEPTOR ACTIVITY |
| EP1685151A4 (en) * | 2003-10-31 | 2009-04-22 | Neuren Pharmaceuticals Ltd | PEPTIDES FOR THE REGENERATION OF NERVES AND METHOD FOR THEIR APPLICATION IN THE TREATMENT OF BRAIN DAMAGES |
| WO2006121926A2 (en) * | 2005-05-06 | 2006-11-16 | Neuren Pharmaceuticals Limited | Neural regeneration peptides and methods for their use |
| WO2007011595A2 (en) * | 2005-07-15 | 2007-01-25 | Neuren Pharmaceuticals Limited | Neural regeneration peptides and antioxidants protect neurons from degeneration |
| DK2212349T3 (da) * | 2007-10-17 | 2013-11-04 | Curonz Holdings Company Ltd | Syntetiske analoger af nerveregenationspeptider |
-
2008
- 2008-10-17 DK DK08840727.5T patent/DK2212349T3/da active
- 2008-10-17 HR HRP20131016AT patent/HRP20131016T1/hr unknown
- 2008-10-17 PT PT88407275T patent/PT2212349E/pt unknown
- 2008-10-17 AU AU2008314565A patent/AU2008314565B2/en not_active Ceased
- 2008-10-17 PL PL08840727T patent/PL2212349T3/pl unknown
- 2008-10-17 WO PCT/US2008/011951 patent/WO2009051844A1/en not_active Ceased
- 2008-10-17 JP JP2010529981A patent/JP5425086B2/ja not_active Expired - Fee Related
- 2008-10-17 ES ES08840727T patent/ES2433568T3/es active Active
- 2008-10-17 NZ NZ585363A patent/NZ585363A/en not_active IP Right Cessation
- 2008-10-17 EP EP08840727.5A patent/EP2212349B1/en active Active
-
2010
- 2010-04-06 US US12/754,937 patent/US8309684B2/en active Active
-
2012
- 2012-10-15 US US13/651,884 patent/US9040485B2/en active Active
-
2013
- 2013-11-05 CY CY20131100977T patent/CY1114619T1/el unknown
-
2015
- 2015-05-01 US US14/701,991 patent/US9650418B2/en not_active Expired - Fee Related
-
2017
- 2017-04-13 US US15/486,734 patent/US20170218023A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008314565B2 (en) | 2013-12-12 |
| EP2212349A1 (en) | 2010-08-04 |
| US8309684B2 (en) | 2012-11-13 |
| NZ585363A (en) | 2012-05-25 |
| US20170218023A1 (en) | 2017-08-03 |
| HRP20131016T1 (hr) | 2014-01-03 |
| ES2433568T3 (es) | 2013-12-11 |
| US20130231289A1 (en) | 2013-09-05 |
| EP2212349B1 (en) | 2013-08-07 |
| PT2212349E (pt) | 2013-11-07 |
| EP2212349A4 (en) | 2010-09-29 |
| AU2008314565A1 (en) | 2009-04-23 |
| US20110098228A1 (en) | 2011-04-28 |
| WO2009051844A1 (en) | 2009-04-23 |
| US20150307553A1 (en) | 2015-10-29 |
| CY1114619T1 (el) | 2016-10-05 |
| US9040485B2 (en) | 2015-05-26 |
| PL2212349T3 (pl) | 2014-01-31 |
| JP2011512322A (ja) | 2011-04-21 |
| US9650418B2 (en) | 2017-05-16 |
| JP5425086B2 (ja) | 2014-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0823379A2 (pt) | Análogos de glucagon | |
| BRPI0823377A2 (pt) | análogos de glucagon | |
| BRPI0823378A2 (pt) | análogos de glucagon | |
| BRPI0823376A2 (pt) | Análagos de glucagon | |
| PT2260053E (pt) | Análogos de oxitocina | |
| BRPI0922913A2 (pt) | Análogos cíclicos de peptídeo 4-amino-4-oxobutanoil inibidores de replicação viral | |
| BRPI0922508A2 (pt) | Análogos de nucleosídeo | |
| DK2248812T3 (da) | Fused cyclic compounds as GPR40 receptor modulators | |
| EP2139906A4 (en) | aminophosphine | |
| BRPI0810482A2 (pt) | Métodos de produção de proteína usando compostos antissenescência | |
| BRPI0815096A2 (pt) | Sulfonamidas como moduladores de trpm8 | |
| SMT201400023B (it) | Analoghi di buprenorfina | |
| DK2598514T3 (da) | Proteinoprensning | |
| DK2197952T3 (da) | Polypropylenblanding | |
| DK2212349T3 (da) | Syntetiske analoger af nerveregenationspeptider | |
| BR112013024784A2 (pt) | análogos de peptídeos de ação prolongada | |
| DK2111555T3 (da) | Diagnosticering af præeklampsi | |
| EP2228036A4 (en) | THE NERVE REGENERATION PLEASANT TUBE | |
| BRPI0814876A2 (pt) | Análogos de pirona fosforilados e métodos | |
| DK2178900T3 (da) | Oprensning af pegylerede polypeptider | |
| CR10675A (es) | Analogos de 2-fenoxipirimidinona | |
| DK2427775T3 (da) | Peptidligander af somatostatinreceptorer | |
| BRPI0922716A2 (pt) | purificação de polipeptídeo | |
| JP2010531899A5 (ja) | 多機能性シリコーン混合物 | |
| BRPI0920845A2 (pt) | uso de análogos de ácido heteroaromáticos contendo enxofre |